InMed Pharmaceuticals Inc.

InMed Pharmaceuticals Inc. Pivots: Exits Commercial Business, Focuses Solely on Drug Development

InMed Pharmaceuticals Inc. is making a dramatic strategic shift, as detailed in its recent 8-K filing. The company will discontinue all commercial operations to concentrate exclusively on pharmaceutical drug development. This summary highlights the critical implications of this move for investors.

1. The Strategic Shift: Winding Down Commercial Operations InMed Pharmaceuticals Inc. will wind down BayMedica LLC, its commercial arm, which sold rare, non-intoxicating cannabinoids. This commercial segment was InMed's sole source of revenue, generating approximately $2.1 million in the nine months ended December 31, 2025, and $2.8 million for the fiscal year ended June 30, 2025. With BayMedica's closure, InMed will become a company solely focused on pharmaceutical research and development (R&D), with no anticipated product sales in the foreseeable future.

2. Timeline of Events InMed's Board of Directors officially approved this strategic decision on March 4, 2026. BayMedica aims to largely complete its wind-down and cease commercial operations by the end of InMed's fiscal year, June 30, 2026. During this period, BayMedica will continue limited sales and operations to manage inventory and ensure an orderly transition. The company publicly announced this decision via press release on March 6, 2026.

3. Rationale: Regulatory Environment and Strategic Re-focus A new federal law, H.R. 5371 (the "Act"), primarily drives this pivot. Expected to take effect on November 12, 2026, the Act, in its current form, will likely prohibit the sale and distribution of certain cannabinoid products and inventory that formed BayMedica's core business, effectively outlawing its primary product line. In response, InMed will now exclusively focus on advancing its pharmaceutical drug candidates:

• INM-901: Targeting Alzheimer's disease.
• INM-089: For dry Age-related Macular Degeneration. The company's goal is to progress these candidates toward Investigational New Drug (IND) applications, a crucial step before human clinical trials.

4. Financial and Operational Impact

• Complete Revenue Loss: InMed will lose its entire revenue stream when BayMedica ceases operations. While BayMedica generated revenue, it was not yet profitable and contributed to InMed's overall net losses.
• Increased Cash Burn & Funding Dependence: As a company focused only on R&D, InMed's operational expenses will almost entirely fund drug development, leading to a significant cash burn. The company will rely entirely on external capital raises (e.g., equity offerings, debt, grants) to finance its operations.
• Wind-down Costs: InMed expects to incur approximately $550,000 in severance and employee-related costs, plus an additional $120,000 in other expenses through the fiscal year-end (June 30, 2026). These costs will reduce the company's cash reserves.
• Current Financial Position: The 8-K filing didn't provide details on InMed's current cash reserves or how much cash they expect to burn through for R&D after BayMedica closes. This is super important information for investors to figure out how long the company can operate without needing more money.

5. Risks and Strategic Implications for Investors

• Elevated Risk Profile: Transitioning to a biotechnology company focused solely on drug development significantly increases InMed's risk profile. Drug development is a lengthy, capital-intensive process with high failure rates (e.g., over 90% of drug candidates fail in clinical trials).
• Clinical Trial Risks: Success depends on positive clinical trial outcomes, regulatory approvals, and eventual market adoption. Failure at any stage (preclinical, IND, Phase 1, 2, 3) could lead to substantial value loss.
• Dilution Risk: To fund its R&D pipeline, InMed will likely need to raise substantial capital, potentially through equity offerings, which could significantly dilute existing shareholders.
• Competitive Landscape: The Alzheimer's and Age-related Macular Degeneration markets are highly competitive, with many established pharmaceutical companies and emerging biotechs.
• Intellectual Property: The company's future value will heavily depend on the strength and enforceability of its intellectual property for INM-901 and INM-089.
• Long-Term Horizon: Any potential revenue from drug sales is many years away, requiring investors to have a very long-term investment horizon and high tolerance for risk.

6. Pipeline Status and Future Outlook

• INM-901 (Alzheimer's): Currently in the preclinical stage, focusing on studies required for an IND application.
• INM-089 (Dry AMD): Also in the preclinical stage, with efforts directed towards IND-enabling studies. InMed's immediate future hinges on successfully completing preclinical work, securing regulatory approval for IND applications, and initiating human clinical trials. Each stage of drug development (preclinical, Phase 1, Phase 2, Phase 3, regulatory approval) is costly, time-consuming, and carries a significant risk of failure. InMed's ability to secure sufficient funding will be paramount to advancing these programs.

7. Investor Takeaways

• Fundamental Business Model Change: InMed is no longer a company with commercial sales; it is now a speculative biotechnology investment.
• Cash Position and Burn Rate are Key: Investors must scrutinize the company's cash reserves, projected R&D expenses, and future funding plans.
• Deep Dive into Pipeline: Understanding the science, market potential, and competitive landscape for INM-901 and INM-089 is more critical than ever.
• High Risk, High Reward: This strategic shift amplifies both the potential for significant gains (if drugs succeed) and the risk of substantial loss (if drugs fail or funding is insufficient).
• Expect Volatility and Potential Dilution: The stock will likely experience increased volatility, and future capital raises will likely involve shareholder dilution.